BiosySyn - proposes rights issue of 1 for 2 at HK$0.068 per share

Gujarat Themis Biosyn Ltd (GTBL) has recently announced a series of corporate actions, including shareholder meetings, compliance certifications, and financial disclosures, reflecting ongoing governance and operational developments. The company reported a 3.93% decline in net profit for Q3 2025, with earnings at ₹12.46 crore, amid a backdrop of evolving management and strategic initiatives. Historical financial data indicates fluctuating operating profits and EPS, with a notable increase in EPS to ₹5.43 in 2025, followed by a decline to ₹4.38 in the subsequent period. GTBL, a manufacturer of pharmaceuticals and medicinal chemicals, has a joint venture with Gedeon Richter Ltd and has collaborated with Yuhan Corporation for the production of anti-tuberculosis drugs. The company has also undertaken significant borrowings, rising from ₹9 crore to ₹71 crore, indicating a shift in its capital structure. In a separate development, ImmunityBio, Inc. recently secured $80 million in equity financing to support its immunotherapy research and operations, while Axion BioSystems completed a $6 million equity round to expand its life science instrumentation business. These developments highlight the dynamic nature of the biosciences and pharmaceutical sectors, where capital raising and strategic partnerships play a pivotal role in sustaining growth and innovation.